SEC Form 4 · accession 0001103780-16-000083
Lexaria Bioscience Corp. · LXRP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher Bunka
Officer — CEO · Director · 10% Owner
Period of report
Jan 20, 2010
Accepted (ET)
Jul 15, 2016 · 7:13 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001348362
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Shares | Jul 14, 2016 | P | 8,800 | $0.10 | A | 7,040,114 | D | |
| Common Shares | Jul 14, 2016 | P | 5,000 | $0.135 | A | 7,045,114 | D | |
| Common Shares | Jul 15, 2016 | P | 5,000 | $0.135 | A | 7,050,114 | D | |
| Common Shares | Jul 15, 2016 | P | 7,400 | $0.1195 | A | 7,057,514 | D | |
| Common Shares | Jul 15, 2016 | P | 5,105 | $0.1194 | A | 7,062,619 | D | |
| Common Shares | Jul 15, 2016 | P | 6,000 | $0.1194 | A | 7,068,619 | D | |
| Common Shares | Jul 15, 2016 | P | 10,000 | $0.1195 | A | 7,078,619 | D | |
| Common Shares | Jul 15, 2016 | P | 7,000 | $0.11 | A | 7,085,619 | D | |
| Common SharesF1 | Jul 15, 2016 | P | 8,000 | $0.13 | A | 7,093,619 | D | |
| Common Shares | holding | — | — | — | 4,971,844 | I | Private holding company | |
| Common Shares | holding | — | — | — | 7,031,314 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options | $0.10 | holding | — | — | — | Dec 23, 2014 | Dec 23, 2019 | Common Shares | 550,000 | 550,000 | D |
| Stock Options | $0.09 | holding | — | — | — | Jun 18, 2013 | Jun 18, 2018 | Common Shares | 247,500 | 797,500 | D |
| Warrants | $0.23 | holding | — | — | — | May 15, 2015 | May 15, 2017 | Common Shares | 187,000 | 187,000 | I |
Explanation of responses
- F1Canadian Dollars